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Regulation of the PTEN tumor suppressor protein is poorly understood. In this issue, Wang 
et al. (2007) and Trotman et al. (2007) describe how ubiquitination regulates PTEN stability 
and its nuclear localization. Additionally, Shen et al. (2007) report that a nuclear pool of 
PTEN helps to maintain chromosomal stability.The PTEN (Phosphatase and TENsin homolog) tumor 
suppressor is one of the most frequently mutated genes 
in human cancer. Somatic mutations in PTEN, which 
result in its inactivation, occur in multiple sporadic tumor 
types. Germline mutations of PTEN cause the inherited 
hamartoma and cancer predisposition syndrome Cow-
den disease (Chow and Baker, 2006). PTEN is the central 
negative regulator of the Phosphatidylinositol-3-kinase 
(PI3K) signal transduction cascade. The class I family 
of PI3 kinases are activated downstream of receptor 
tyrosine kinases (RTK) or G protein-coupled receptors 
(GPCR) to catalyze the conversion of phosphatidylinosi-
tol 4,5 phosphate (PIP2) to phosphatidylinositol 3,4,5 
phosphate (PIP3) leading to the activation of AKT kinase 
and other downstream effectors (Engelman et al., 2006). 
PTEN is a lipid phosphatase that dephosphorylates PIP3 
at the plasma membrane and thereby inhibits PI3K-
mediated signals for growth, proliferation, and survival 
(Figure 1). Despite its well-defined role in signaling at the 
plasma membrane, PTEN is found in the nucleus in a 
number of different normal and tumor cell types. Intrigu-
ingly, nuclear localization of PTEN may contribute to its 
tumor suppressor activity (Lian and Di Cristofano, 2005). 
Given that many of the main components of the PI3K 
signaling pathway are found in the nucleus—including 
PIP2, PIP3, PI3K, PDK1, and AKT (Deleris et al., 2006)—
it is possible that PTEN is a PIP3 phosphatase in the 
nucleus as well. However, a recent study suggests that 
nuclear PTEN does not dephosphorylate the nuclear 
pool of PIP3 (Lindsay et al., 2006). Other studies have 
implicated phosphatase-independent functions of PTEN 
within the nucleus including protein-protein interactions 
that modulate the activity and stability of p53 (Li et al., 
2006; Lian and Di Cristofano, 2005).
In this issue of Cell, three exciting papers (Shen et al., 
2007; Trotman et al., 2007; Wang et al., 2007) provide 
insights into the role of ubiquitination in regulating PTEN 
stability and its nuclear localization, as well as the func-
tion of nuclear PTEN in chromosomal stability (Figure 1).
PTEN Degradation
PTEN contains two PEST motifs, which are frequently 
found in proteins targeted for degradation by the ubiqui-
tin pathway. In this issue, Wang et al. (2007) investigated the role of ubiquitin-mediated degradation of PTEN. 
After demonstrating that overexpressed PTEN was 
polyubiquitinated in cells, they used an in vitro polyu-
biquitination assay to identify NEDD4-1 (neural precur-
sor cell expressed, developmentally downregulated 4-1) 
as the E3 ubiquitin ligase that specifically targets PTEN 
Figure 1. Proposed Nuclear and Cytoplasmic Function and 
Regulation of PTEN
In the cytoplasm, PI3K is activated downstream of receptor tyrosine 
kinases and G protein-coupled receptors to convert PIP2 to PIP3, 
leading to AKT activation and enhanced growth, proliferation, and 
survival. PTEN phosphatase antagonizes PI3K by converting PIP3 to 
PIP2. Wang et al. (2007) show that NEDD4-1 polyubiquitinates PTEN, 
promoting its degradation in the cytoplasm, while Trotman et al. (2007) 
show that monoubiquitination increases nuclear localization of PTEN. 
Nuclear PTEN could function as a lipid phosphatase as it does in the 
cytoplasm but may also be involved in maintaining genomic integrity 
as shown by Shen et al. (2007).Cell 128, January 12, 2007 ©2007 Elsevier Inc. 25
for ubiquitination. NEDD4-1 and PTEN showed a direct 
physical interaction, and overexpression of NEDD4-1 
resulted in polyubiquitination and proteasomal degra-
dation of endogenous PTEN. Conversely, knockdown of 
NEDD4-1 by RNAi increased the levels and stability of 
overexpressed PTEN.
These data suggest that NEDD4-1 may contribute 
to oncogenesis by inhibiting PTEN tumor suppressor 
activity. p53-deficient MEFs were transformed by Pten 
deletion (Chen et al., 2005) but were not transformed by 
NEDD4-1 overexpression, most likely because Pten pro-
tein, although diminished, remained sufficient for tumor 
suppression. Although NEDD4-1 was not oncogenic 
alone, its overexpression enhanced Ras-mediated trans-
formation of p53-deficient mouse embryonic fibroblasts 
(MEFs). Importantly, this effect was not observed in 
Pten-deficient cells, indicating that the oncogenic activ-
ity of NEDD4-1 is PTEN dependent.
To evaluate NEDD4-1 in a more physiological context, 
Wang et al. (2007) analyzed a mouse model for prostate 
cancer in which the onset and rate of prostate tumorigen-
esis is directly correlated with decreased levels of Pten 
expression (Trotman et al., 2003). Using immunohisto-
chemistry, they showed that neoplastic lesions in the 
prostate with decreased Pten levels contained increased 
amounts of Nedd4-1, thereby associating increased 
Nedd4-1 levels with oncogenesis. Furthermore, knock-
down of NEDD4-1 by RNAi inhibited xenograft growth of 
a prostate tumor cell line expressing PTEN but had no 
effect on tumor growth of a PTEN-deficient cell line.
NEDD4-1 may not have oncogenic activity in all con-
texts, as it may not completely deplete PTEN levels. Are 
there human tumor types in which partial inactivation of 
PTEN is sufficient for oncogenesis? Many different types 
of sporadic tumors show frequent allelic deletion of 
PTEN but retain a wild-type allele. In these tumors, PTEN 
haploinsufficiency may or may not contribute to tumori-
genesis. In a large collection of invasive human bladder 
cancers, there was an association between higher lev-
els of NEDD4-1 message and decreased PTEN protein. 
However, there was not a consistent inverse correlation 
between NEDD4-1 and PTEN expression as would be 
predicted from a simple model where NEDD4-1 is the 
predominant regulator of PTEN steady-state levels.
A precedent for ubiquitin-mediated regulation of 
tumor suppressor activity is provided by MDM2, which 
ubiquitinates p53 and promotes its degradation. Ampli-
fication of MDM2 in tumors with wild-type p53 provided 
compelling genetic evidence that MDM2 can function as 
an oncogene in human tumors. Identification of NEDD4-
1 amplification in primary tumors would provide exciting 
evidence for oncogenic activity of this ubiquitin ligase 
in human cancer. Additional information about how 
NEDD4-1 is regulated, which tissues and physiological 
settings involve appreciable loss of PTEN due to NEDD4-
1-mediated ubiquitination, what alternative proteins are 
also targeted by NEDD4-1-mediated ubiquitination, and 
whether other ubiquitin ligases also modify PTEN will 26 Cell 128, January 12, 2007 ©2007 Elsevier Inc.provide critical insights into whether NEDD4-1 inhibition 
would be an effective therapeutic approach.
PTEN Ubiquitination: More than Meets the Eye
Also in this issue, Trotman et al. (2007) show that pre-
dicting the physiological outcome of NEDD4-1-medi-
ated ubiquitination of PTEN is indeed quite complicated. 
They investigated a lysine to glutamate mutation in PTEN 
(K289E) identified in a Cowden syndrome family. Previ-
ous studies showed that this mutation did not disrupt 
the phosphatase activity or membrane localization of 
the mutated PTEN protein (Georgescu et al., 2000). In 
intestinal polyps obtained from a patient with an inher-
ited K289E mutation, the wild-type PTEN allele was 
deleted, leaving only expression of the mutated allele. 
Using an intestinal polyp from a patient with this germline 
mutation, Trotman et al. (2007) showed that the K289E 
mutant protein was excluded from the nuclei of dysplas-
tic epithelial cells. They next showed that overexpres-
sion of a GFP-PTEN K289E fusion protein resulted in 
predominantly cytoplasmic PTEN localization whereas 
a wild-type GFP-PTEN fusion protein was found in the 
nucleus and cytoplasm. This aberrant localization was 
not dependent on PTEN phosphatase activity but was 
due to a dramatic decrease in nuclear import, without 
enhancing nuclear export.
The authors showed that NEDD4-1 was capable of 
ubiquitinating K289, along with a number of other sites 
on PTEN. Overexpression of PTEN K289E showed that 
this mutation resulted in decreased PTEN monoubiquiti-
nation, although specific ubiquitination of K289 was not 
demonstrated directly in cells. Lysine 13 was identified 
as a second site of ubiquitination in transfected cells. 
A mutation in this lysine, K13E—originally identified in 
sporadic brain cancer—also disrupted nuclear localiza-
tion and decreased the rate of nuclear import. Ubiqui-
tin overexpression increased the rate of PTEN nuclear 
import, and overexpression of a mutated ubiquitin 
capable of only monoubiquitination resulted in a much 
greater increase.
This study shows a strong increase in nuclear PTEN 
associated with increased ubiquitination, particularly 
monoubiquitination. However, this effect could be medi-
ated by ubiquitination of other substrates unrelated to 
PTEN. Therefore, PTEN localization was evaluated in 
the absence and presence of NEDD4-1. Knockdown of 
NEDD4-1 redistributed PTEN to the cytoplasm, whereas 
overexpression of NEDD4-1 increased nuclear PTEN 
localization. Monoubiquitinated PTEN was enriched in the 
nuclear fraction; however, the entire population of nuclear 
PTEN was not monoubiquitinated, suggesting that ubiq-
uitin is removed from PTEN in the nucleus or that a pro-
portion of nuclear PTEN was imported without ubiquitina-
tion. Clearly, the identification of PTEN-deubiquitinating 
enzymes in the nucleus would elucidate another level of 
regulation in PTEN stability and localization.
Interestingly, MDM2-mediated ubiquitination of p53 
enhances its nuclear export and cytoplasmic degrada-
tion. In contrast, monoubiquitination mediated transport 
into the nucleus and increased PTEN stability (Trot-
man et al., 2007), whereas polyubiquitination of PTEN 
by NEDD4-1 enhanced degradation of PTEN (Wang et 
al., 2007) (Figure 1). Are these two opposing outcomes 
regulated through control of the ubiquitination process? 
It will be particularly interesting to determine if ubiq-
uitination works in concert with previously identified 
mechanisms of PTEN turnover and nuclear localization. 
For example, phosphorylation of the C-terminal tail influ-
ences PTEN stability, although the physiological stimuli 
that influence this process remain unclear (Okahara 
et al., 2004; Vazquez et al., 2000). PTEN containing a 
mutation in K289 was excluded from nuclei, presumably 
because of decreased monubiquitination of this lysine. 
However, monoubiquitination of K289 is not required 
for PTEN nuclear import, as shown by both nuclear and 
cytoplasmic localization of a number of C-terminal dele-
tion mutants lacking K289 (Shen et al., 2007). Several 
different modes of regulation for PTEN nuclear import 
have been described including passive transport by dif-
fusion, active transport via putative nuclear localization 
signals within the C terminus of PTEN (Lian and Di Cris-
tofano, 2005 and references therein), and Ran-depend-
ent import mediated by an N-terminal nuclear localiza-
tion domain along with multiple nuclear exclusion motifs 
(Gil et al., 2006). It is possible that monoubiquitination 
provides a signal for enhanced transport to the nucleus 
through some of these mechanisms, or through an inde-
pendent process.
PTEN and Genomic Integrity
How does PTEN nuclear localization influence tumor 
suppression? Previous studies showed that PTEN loss 
contributed to genomic instability through cytoplasmic 
signaling by causing increased AKT-mediated seques-
tration of the kinase CHK1, thereby compromising 
the G2/S phase checkpoint in response to DNA dam-
age (Puc et al., 2005). In this issue, Shen et al. (2007) 
investigated the association between PTEN deficiency 
and aneuploidy. They showed that Pten-deficient MEFs 
contained an increased number of chromosomal frag-
ments with breakage at the centromeres, breakage of 
chromatids, and reciprocal translocations compared to 
wild-type MEFs. The frequency of chromosomal insta-
bility was much lower in Pten-deficient embryonic stem 
cells than in MEFs, suggesting that the contribution of 
Pten to genomic stability may vary between cell types. 
The nuclear pool of endogenous Pten protein colo-
calized with centromeres in MEFs, and Pten could be 
coimmunoprecipitated with the core centromeric pro-
tein Cenp-C, which is required for proper kinetochore 
assembly and for the metaphase to anaphase transition 
during mitosis.
Using mutations of PTEN that were originally identi-
fied in Cowden syndrome patients, Shen et al. (2007) 
showed that the C terminus, but not the phosphatase 
domain of PTEN, was required for interaction with Cenp-C and with centromeres. In wild-type cells, expression of 
C-terminally truncated PTEN proteins abrogated binding 
of endogenous wild-type Pten to Cenp-C and induced 
chromosomal abnormalities without affecting levels of 
phospho-Akt. This suggests that expression of a mutant 
PTEN lacking the C terminus can interfere with normal 
function of PTEN at the centromeres without affect-
ing its cytoplasmic activity. Mechanistic experiments 
are required to determine if and how PTEN interaction 
influences CENP-C function in kinetochore assembly or 
metaphase to anaphase transition.
The chromatid breaks and translocations observed in 
Pten-deficient MEFs suggested a potential defect in the 
repair of DNA damage. Indeed, Shen et al. (2007) found 
that Pten-deficient MEFs showed increased nuclear foci 
containing phosphorylated histone H2AX and p53-bind-
ing protein 1, both of which bind to DNA double-strand 
breaks (DSBs). This is consistent with previous reports 
of increased nuclear foci containing phosphorylated 
H2AX following knockdown of PTEN by RNAi (Kim et 
al., 2006; Puc and Parsons, 2005). A survey for expres-
sion changes in DNA DSB repair genes in Pten-deficient 
MEFs identified a significant decrease in the mRNA and 
protein for Rad51, an essential component of homolo-
gous recombination and repair of DNA DSBs. Enforced 
expression of Rad51 in Pten-deficient MEFs decreased 
DSBs to levels that were comparable to wild-type MEFs, 
demonstrating a functional connection between depleted 
Rad51 levels and DSBs. Similarly, the PTEN null prostate 
cancer cell line PC-3 expressed very little RAD51, and 
exogenous PTEN expression induced RAD51 and dimin-
ished the occurrence of DNA DSBs in these cells.
A connection between PTEN loss and transcriptional 
regulation of Rad51 was unexpected. PTEN is known to 
influence transcription through inhibition of AKT-medi-
ated phosphorylation and sequestration of the FOXO 
family of transcription factors (Chow and Baker, 2006; 
Engelman et al., 2006). This requires the phosphatase 
activity of PTEN and could potentially involve both cyto-
plasmic and nuclear PTEN. Shen et al. (2007) suggest a 
more direct impact of PTEN on transcription regulation, 
as they detected Pten bound to the Rad51 promoter by 
a chromatin-IP (ChIP) assay. Given the diverse functions 
already attributed to PTEN, it will be important to dem-
onstrate that PTEN binds to DNA in a sequence-specific 
manner, as nonspecific binding of PTEN to DNA could 
give the same result in the ChIP assay. Although PTEN 
did not directly activate transcription of a Rad51 pro-
moter reporter construct, PTEN expression enhanced 
E2F-mediated transactivation of this construct. Overex-
pression of PTEN can affect cell-cycle regulation of cul-
tured cells, with outcome varying based on the cell line 
and the levels of exogenous expression. It is possible 
that E2F-mediated changes in Rad51 promoter activa-
tion could have been an indirect result of PTEN-medi-
ated cell-cycle effects. Shen et al. (2007) postulated that 
Pten may cooperate with E2F-mediated transcription 
of Rad51 by influencing chromatin remodeling of the Cell 128, January 12, 2007 ©2007 Elsevier Inc. 27
Rad51 promoter. This mechanism does not explain the 
Pten-mediated effect in the transient transfection assay 
where the DNA reporter construct lacked histones. 
However, a connection between PTEN and chroma-
tin remodeling is possible. Recent studies have shown 
interactions between PTEN and the transcriptional 
coactivators PCAF and p300 that function as histone 
acetyltransferases. These interactions are likely to result 
in complex functional outcomes beyond an influence 
on histone acetylation, as PCAF-mediated acetylation 
of PTEN can modulate PTEN phosphatase activity, and 
the interaction between PTEN and p53 stimulates p300-
mediated acetylation of p53 (Li et al., 2006; Okumura et 
al., 2006).
Concluding Remarks
Taken together, the three papers in this issue raise a 
number of important questions about PTEN regulation 
and tumor suppression. What are the physiological sig-
nals to regulate PTEN stability, activity, and localization? 
When and how is disruption of this regulation involved 
in tumorigenesis? What is the relative contribution of 
nuclear PTEN and genomic stability to tumor suppres-
sion compared with its role as a cytoplasmic lipid phos-
phatase regulating PI3K signaling? Are all functions 
attributed to PTEN important for tumor suppression in 
every context, or are distinct activities engaged in par-
ticular oncogenic settings?
PTEN can participate in a number of cellular proc-
esses relevant to tumorigenesis including regulation of 
proliferation and survival, cell migration and invasion, 
angiogenesis, genomic instability, induction of cell-cycle 
checkpoints in response to DNA damage, and stem cell 
self-renewal (Chow and Baker, 2006 and references 
therein). This wide range of activities spans both the 
nucleus and the cytoplasm. Many but not all of these 
functions require the lipid phosphatase activity of PTEN 
that directly regulates PIP3 levels. In tumors with point 
mutations that selectively inactivate phosphatase activ-
ity, the phosphatase-independent activities of PTEN are 
presumably intact and therefore not involved. The Shen 
et al. (2007) and Trotman et al. (2007) studies made use 
of rare mutations found in Cowden syndrome patients. 
Analysis of these mutations that retained the phos-
phatase domain of PTEN, but deleted or mutated key 
residues in the C terminus, revealed novel insights into 
previously uncharacterized aspects of PTEN function. 
Are the ubiquitin-mediated regulation of PTEN stability 
and nuclear localization and the role of PTEN in chro-
mosomal stability relevant for all tumors in which PTEN 
activity is compromised? Because the Cowden syn-
drome mutations tested in these studies are quite rare, 
it is impossible to evaluate patient information to deter-
mine whether these mutations could give rise to the full 
spectrum of disease associated with PTEN deficiency. 
It is likely that distinct subsets of PTEN functions are 
essential for tumor suppression in particular tissue types 
and in response to different combinations of oncogenic 28 Cell 128, January 12, 2007 ©2007 Elsevier Inc.stimuli. Mouse models containing knockin mutations 
of key residues in the C terminus will help to determine 
whether effects on localization and chromosome stabil-
ity are observed in all tissues and are associated with a 
tumor spectrum similar to null mutations studied in Pten 
heterozygous or conditional knockout mice. Under-
standing the specific involvement of the PTEN pathway 
in particular tumors, and the cellular players that may be 
modulated to influence these functions, will provide the 
necessary foundation for successful development and 
informed use of pathway inhibitors for cancer therapy.
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